Blood test to guide chemotherapy for her2-positive and triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study is testing a way to use a simple blood test during chemotherapy to see how well the treatment is working in certain breast cancers. The goal is to make sure you get the best treatment for your tumor type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II or III breast cancer that is either HER2-positive or triple-negative.
- You have not had any previous treatment for this breast cancer (like chemotherapy, hormone therapy, surgery, or radiation).
- You have at least one tumor that can be measured on an ultrasound (at least 1 cm in size).
- You are fit enough to receive chemotherapy before surgery and are eligible for surgery afterward.
- You are willing to have extra blood tests and a tumor biopsy during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
This study examines tiny particles in your blood from breast cancer cells to better predict which treatments will work best for you. Researchers will collect blood samples and a small tissue sample to understand your cancer's characteristics and help doctors choose more effective therapy.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This study tests a new blood test to see if it can find tiny bits of tumor DNA after chemotherapy. If you have a larger or higher-risk breast cancer and are getting chemotherapy before surgery, you may join. The test could help doctors know if your cancer is gone or if more treatment is needed.
This trial uses a simple blood test to look for leftover cancer DNA in people with triple-negative breast cancer who still have disease after chemotherapy and surgery. It aims to catch any early signs of the cancer coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.